Winship Cancer Institute at Emory University
Welcome,         Profile    Billing    Logout  
 46 Trials 
77 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Blum, Kristie
NCT03015896: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Active, not recruiting
1/2
36
US
Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
David Bond, MD, Bristol-Myers Squibb
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
12/24
12/24
NCT05879744: A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Active, not recruiting
1
90
US
CLN-978
Cullinan Therapeutics Inc.
NHL, NHL, Relapsed, Adult
11/26
04/27
Cohen, Jonathan
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Active, not recruiting
3
1457
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
07/24
04/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT05212818 / 2021-000748-24: Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults

Terminated
2
19
US, RoW
TF0023, IP, Active drug
Techfields Inc
COVID-19 Pneumonia
02/23
03/23
NCT05130970 / 2021-003162-12: Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Completed
2
81
Europe, Canada, US, RoW
Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo
CSL Behring
Idiopathic Pulmonary Fibrosis
01/24
01/24
IPF COMFORT, NCT05185089 / 2021-006278-22: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Completed
2
80
Europe, US
Orvepitant Maleate, Placebo
Nerre Therapeutics Ltd., Pharm-Olam International
Cough, Idiopathic Pulmonary Fibrosis
06/24
06/24
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Recruiting
1/2
285
Europe, US, RoW
SAR445877, Cetuximab, Erbitux
Sanofi, Sanofi Aventis Recherche & Développement
Solid Tumor
01/27
09/28
NCT03786926: Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Active, not recruiting
1
53
Europe, US
HMPL-689
Hutchmed
Lymphoma
07/24
12/24
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26
BND-35-001, NCT06274437: A Study of BND-35 in Participants With Advanced Solid Tumors

Recruiting
1
280
RoW
BND-35, Monoclonal antibody, Nivolumab, Opdivo, Cetuximab, Erbitux
Biond Biologics
Cancer
09/27
11/27
KEYNOTE-E92, NCT05378425: A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Recruiting
1
90
US, RoW
NTX-1088, Pembrolizumab, KEYTRUDA®
Nectin Therapeutics Ltd, Merck Sharp & Dohme LLC
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
06/25
12/25
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Santin, Alessandro
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
NCT03832361: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Recruiting
2
50
US
IMGN853, mirvetuximab soravtansine
Alessandro Santin, ImmunoGen, Inc.
Endometrial Cancer
10/25
10/28
NCT02899793: Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Active, not recruiting
2
25
US
Pembrolizumab, MK-3475
Yale University, Merck Sharp & Dohme LLC
Recurrent Endometrial Cancer
10/25
10/25
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT04251416: A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Recruiting
2
50
US
Sacituzumab Govitecan, IMMU-132
Yale University, Gilead Sciences
Endometrial Carcinoma
12/25
02/26
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NCT02491099: A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Recruiting
2
50
US
Afatinib, Irreversible Human Epidermal Growth Factor
Yale University, Boehringer Ingelheim
HER2/Neu+ Uterine Serous Carcinoma
07/25
07/25
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
NCT06028932: A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Recruiting
2
20
US
Sacituzumab govitecan, IMMU-132
Yale University, Gilead Sciences
Ovarian Carcinoma
11/25
11/27
NCT05838521: A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Recruiting
2
20
US
Sacituzumab govitecan, Trodelvy
Yale University, Gilead Sciences
Cervical Cancer
06/26
06/28
STRO-002-GM1, NCT03748186: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Completed
1
136
Europe, US
STRO-002
Sutro Biopharma, Inc.
Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/24
06/24
Arellano, Martha
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 
Kaufman, Jonathan
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
NCT04123418: A Study of WVT078 in Patients With Multiple Myeloma (MM)

Terminated
1
56
Europe, Japan, US, RoW
WVT078, WHG626
Novartis Pharmaceuticals
Multiple Myeloma (MM)
12/24
12/24
El-Rayes, Bassel F
NCT04191421: Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Completed
1/2
42
US
Siltuximab, Anti-IL-6 Chimeric Monoclonal Antibody, cCLB8, CNTO 328, Sylvant, Spartalizumab, PDR001
Emory University, Novartis, EUSA Pharma, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
04/23
04/23
Master, Viraj
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Active, not recruiting
N/A
280
Europe, Canada, US
GAG score
Elypta
Clear Cell Renal Cell Carcinoma
05/25
12/25
Williams, Monique
ALTA TIPS, NCT03973372: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement

Recruiting
N/A
1000
US
University of Texas Southwestern Medical Center, University of California, San Francisco, Scripps Health, University of Wisconsin, Madison, University of Florida, University of Arizona, Stanford University, Columbia University, Weill Medical College of Cornell University, Baylor Scott and White Health, Mayo Clinic, University of Chicago, Digestive Health Foundation, W.L.Gore & Associates, University of Minnesota, Northwestern University
Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
07/25
12/27
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
Baker, Lisa
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/29
08/34
NCT03832361: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Recruiting
2
50
US
IMGN853, mirvetuximab soravtansine
Alessandro Santin, ImmunoGen, Inc.
Endometrial Cancer
10/25
10/28
GOG-3039, NCT04393285: Abemaciclib and Letrozole to Treat Endometrial Cancer

Active, not recruiting
2
53
US
Abemaciclib, Letrozole
Gynecologic Oncology Group, Eli Lilly and Company
Endometrial Cancer
12/24
12/25
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT04251416: A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Recruiting
2
50
US
Sacituzumab Govitecan, IMMU-132
Yale University, Gilead Sciences
Endometrial Carcinoma
12/25
02/26
NCT02491099: A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Recruiting
2
50
US
Afatinib, Irreversible Human Epidermal Growth Factor
Yale University, Boehringer Ingelheim
HER2/Neu+ Uterine Serous Carcinoma
07/25
07/25
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
NCT06028932: A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Recruiting
2
20
US
Sacituzumab govitecan, IMMU-132
Yale University, Gilead Sciences
Ovarian Carcinoma
11/25
11/27
NCT05838521: A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Recruiting
2
20
US
Sacituzumab govitecan, Trodelvy
Yale University, Gilead Sciences
Cervical Cancer
06/26
06/28
STRO-002-GM1, NCT03748186: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Completed
1
136
Europe, US
STRO-002
Sutro Biopharma, Inc.
Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/24
06/24
Bilen, Mehmet Asim
NCT03333616: Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Checkmark In combination with Opdivo for advanced genitourinary cancers
May 2020 - May 2020: In combination with Opdivo for advanced genitourinary cancers
Checkmark In combination with Yervoy for advanced genitourinary cancers
May 2020 - May 2020: In combination with Yervoy for advanced genitourinary cancers
Active, not recruiting
2
100
US
Ipilimumab, Yervoy, Nivolumab, Opdivo
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer, Non-adenocarcinoma Prostate Cancer, Refractory Germ-cell, High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
12/24
05/25
NCT04393350: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Recruiting
2
22
US
Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Lenvatinib Mesylate, 4-[3-Chloro-4-(N''-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate, Lenvima, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
01/25
01/26
NCT04022343: Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Active, not recruiting
2
22
US
Cabozantinib, Cometriq, Cabometyx, BMS-907351, XL184, 1140909-48-3
Emory University, Exelixis, National Institutes of Health (NIH), National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
02/22
02/25
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
04/25
06/25
OASIS, NCT06063317: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors

Recruiting
1
33
US
CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto
Imugene Limited
Solid Tumor, Adult
06/27
05/29
NCT04878029: Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Recruiting
1
32
US
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL-184, XL184, Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG-22CE, Enfortumab Vedotin-ejfv, Padcev, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, Exelixis, National Cancer Institute (NCI)
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
01/25
01/26
Akce, Mehmet
NCT05103904: Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Recruiting
2
19
US
Laboratory Biomarker Analysis, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Emory University, National Cancer Institute (NCI), Eisai Co., Ltd.
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC V8, Stage IIIA Hepatocellular Carcinoma AJCC V8, Stage IIIB Hepatocellular Carcinoma AJCC V8, Stage IV Hepatocellular Carcinoma AJCC V8, Stage IVA Hepatocellular Carcinoma AJCC V8, Stage IVB Hepatocellular Carcinoma AJCC V8, Unresectable Hepatocellular Carcinoma
11/25
11/26
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
NCT06728410: A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Not yet recruiting
2
38
US
Pemigatinib, PEMAZYRE, Durvalumab, Imfinzi
Mehmet Akce, AstraZeneca, Incyte Corporation, University of Alabama at Birmingham
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
07/26
07/27
NCT04650451: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Suspended
1/2
220
US
chimeric antigen receptor (CAR) T cell therapy, CAR-T, BPX-603, autologous CAR-T
Bellicum Pharmaceuticals
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
12/25
01/27
NCT06182072: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1
28
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, nab paclitaxel, (G-nP)
ProDa BioTech, LLC, University of Alabama at Birmingham, Georgia State University
Pancreatic Ductal Carcinoma
07/25
10/25
Barton-Judson, Emma
OASIS, NCT06063317: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors

Recruiting
1
33
US
CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto
Imugene Limited
Solid Tumor, Adult
06/27
05/29
Coleman, Kathleen F
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT06460298: ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
1/2
51
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, ProAgio Dose Expansion
ProDa BioTech, LLC, Emory University, Georgia State University
Triple Negative Breast Cancer
07/26
10/26
NCT05304962: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Recruiting
1
64
US
RGT-419B, RGT-419B in combination with hormonal therapy
Regor Pharmaceuticals Inc.
Breast Cancer
12/25
09/26
Diab, Maria
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
NCT03910387: Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Active, not recruiting
2
22
US
Gemcitabine, Gemzar, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI-007, Abraxane, Nanoparticle Albumin-bound Paclitaxel, Telotristat Ethyl, Xermelo
Emory University, National Cancer Institute (NCI), Lexicon Pharmaceuticals
Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
10/23
10/24
NCT03800602: Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

Completed
2
29
US
Metformin, Glucophage, Glumetza, Fortamet, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Emory University, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH)
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage IVC Colorectal Cancer, Colorectal Cancer Metastatic
09/20
09/21
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT04650451: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Suspended
1/2
220
US
chimeric antigen receptor (CAR) T cell therapy, CAR-T, BPX-603, autologous CAR-T
Bellicum Pharmaceuticals
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
12/25
01/27
NCT03095781: Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Completed
1
49
US
XL888, Heat Shock Protein 90 Inhibitor XL888, Hsp90 Inhibitor XL888, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Emory University, Merck Sharp & Dohme LLC, Exelixis, National Institutes of Health (NIH), National Cancer Institute (NCI)
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Pancreatic Carcinoma
06/21
06/21
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
Schmitt, Nicole C
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT05245682: Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Recruiting
1
10
US
Tolinapant, ASTX660, 1799328-86-1, XIAP/cIAP1 Antagonist ASTX660, Radiation Therapy, Cancer Radiotherapy, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT Therapy
Emory University, Astex Pharmaceuticals, Inc.
Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
10/25
10/25
Fernandez, Krystal
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
Caruso, Christina
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31

Download Options